Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 14/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHKA | P35790 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9480589 | 0.79 | KDM4E (0.47) | SIRT2ALDH1A1KDM4ECHRM5CHKA | |
| SCHEMBL8861250 | 0.77 | SIRT2 (0.39) | SIRT2ALDH1A1KDM4ECHRM5CHKA | |
| SCHEMBL7664616 | 0.77 | KDM4E (0.50) | SIRT2ALDH1A1KDM4ECHRM5CHKA | |
| SCHEMBL31182983 | 0.77 | KDM4E (0.46) | SIRT2ALDH1A1KDM4ECHRM5CHKA | |
| SCHEMBL4307694 | 0.77 | KDM4E (0.46) | SIRT2ALDH1A1KDM4ECHRM5CHKA | |
| SCHEMBL29907776 | 0.77 | KDM4E (0.46) | SIRT2ALDH1A1KDM4ECHRM5CHKA | |
| SCHEMBL15212887 | 0.77 | KDM4E (0.46) | SIRT2ALDH1A1KDM4ECHRM5CHKA | |
| SCHEMBL15211555 | 0.77 | KDM4E (0.46) | SIRT2ALDH1A1KDM4ECHRM5CHKA | |
| SCHEMBL4308808 | 0.77 | ALDH1A1 (0.50) | SIRT2ALDH1A1KDM4ECHRM5CHKA | |
| SCHEMBL28056162 | 0.76 | MAOA (0.44) | NOS3NOS1NOS2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507539-B2 | Potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2013-08-13 | — | — | US | disclosed |
| US-20110166130-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166130-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | KCNA3, KCNB1, KCNK3 | SIRT2 1438/4885ALDH1A1 4002/4885KDM4E 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.